Comparison of prognostic scores for inpatients with COVID-19: a retrospective monocentric cohort study.
COVID-19
Journal
BMJ open respiratory research
ISSN: 2052-4439
Titre abrégé: BMJ Open Respir Res
Pays: England
ID NLM: 101638061
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
21
06
2022
accepted:
07
08
2022
entrez:
24
8
2022
pubmed:
25
8
2022
medline:
27
8
2022
Statut:
ppublish
Résumé
The SARS-CoV-2 pandemic led to a steep increase in hospital and intensive care unit (ICU) admissions for acute respiratory failure worldwide. Early identification of patients at risk of clinical deterioration is crucial in terms of appropriate care delivery and resource allocation. We aimed to evaluate and compare the prognostic performance of Sequential Organ Failure Assessment (SOFA), Quick Sequential Organ Failure Assessment (qSOFA), Confusion, Uraemia, Respiratory Rate, Blood Pressure and Age ≥65 (CURB-65), Respiratory Rate and Oxygenation (ROX) index and Coronavirus Clinical Characterisation Consortium (4C) score to predict death and ICU admission among patients admitted to the hospital for acute COVID-19 infection. Consecutive adult patients admitted to the Geneva University Hospitals during two successive COVID-19 flares in spring and autumn 2020 were included. Discriminative performance of these prediction rules, obtained during the first 24 hours of hospital admission, were computed to predict death or ICU admission. We further exluded patients with therapeutic limitations and reported areas under the curve (AUCs) for 30-day mortality and ICU admission in sensitivity analyses. A total of 2122 patients were included. 216 patients (10.2%) required ICU admission and 303 (14.3%) died within 30 days post admission. 4C score had the best discriminatory performance to predict 30-day mortality (AUC 0.82, 95% CI 0.80 to 0.85), compared with SOFA (AUC 0.75, 95% CI 0.72 to 0.78), qSOFA (AUC 0.59, 95% CI 0.56 to 0.62), CURB-65 (AUC 0.75, 95% CI 0.72 to 0.78) and ROX index (AUC 0.68, 95% CI 0.65 to 0.72). ROX index had the greatest discriminatory performance (AUC 0.79, 95% CI 0.76 to 0.83) to predict ICU admission compared with 4C score (AUC 0.62, 95% CI 0.59 to 0.66), CURB-65 (AUC 0.60, 95% CI 0.56 to 0.64), SOFA (AUC 0.74, 95% CI 0.71 to 0.77) and qSOFA (AUC 0.59, 95% CI 0.55 to 0.62). Scores including age and/or comorbidities (4C and CURB-65) have the best discriminatory performance to predict mortality among inpatients with COVID-19, while scores including quantitative assessment of hypoxaemia (SOFA and ROX index) perform best to predict ICU admission. Exclusion of patients with therapeutic limitations improved the discriminatory performance of prognostic scores relying on age and/or comorbidities to predict ICU admission.
Sections du résumé
BACKGROUND
The SARS-CoV-2 pandemic led to a steep increase in hospital and intensive care unit (ICU) admissions for acute respiratory failure worldwide. Early identification of patients at risk of clinical deterioration is crucial in terms of appropriate care delivery and resource allocation. We aimed to evaluate and compare the prognostic performance of Sequential Organ Failure Assessment (SOFA), Quick Sequential Organ Failure Assessment (qSOFA), Confusion, Uraemia, Respiratory Rate, Blood Pressure and Age ≥65 (CURB-65), Respiratory Rate and Oxygenation (ROX) index and Coronavirus Clinical Characterisation Consortium (4C) score to predict death and ICU admission among patients admitted to the hospital for acute COVID-19 infection.
METHODS AND ANALYSIS
Consecutive adult patients admitted to the Geneva University Hospitals during two successive COVID-19 flares in spring and autumn 2020 were included. Discriminative performance of these prediction rules, obtained during the first 24 hours of hospital admission, were computed to predict death or ICU admission. We further exluded patients with therapeutic limitations and reported areas under the curve (AUCs) for 30-day mortality and ICU admission in sensitivity analyses.
RESULTS
A total of 2122 patients were included. 216 patients (10.2%) required ICU admission and 303 (14.3%) died within 30 days post admission. 4C score had the best discriminatory performance to predict 30-day mortality (AUC 0.82, 95% CI 0.80 to 0.85), compared with SOFA (AUC 0.75, 95% CI 0.72 to 0.78), qSOFA (AUC 0.59, 95% CI 0.56 to 0.62), CURB-65 (AUC 0.75, 95% CI 0.72 to 0.78) and ROX index (AUC 0.68, 95% CI 0.65 to 0.72). ROX index had the greatest discriminatory performance (AUC 0.79, 95% CI 0.76 to 0.83) to predict ICU admission compared with 4C score (AUC 0.62, 95% CI 0.59 to 0.66), CURB-65 (AUC 0.60, 95% CI 0.56 to 0.64), SOFA (AUC 0.74, 95% CI 0.71 to 0.77) and qSOFA (AUC 0.59, 95% CI 0.55 to 0.62).
CONCLUSION
Scores including age and/or comorbidities (4C and CURB-65) have the best discriminatory performance to predict mortality among inpatients with COVID-19, while scores including quantitative assessment of hypoxaemia (SOFA and ROX index) perform best to predict ICU admission. Exclusion of patients with therapeutic limitations improved the discriminatory performance of prognostic scores relying on age and/or comorbidities to predict ICU admission.
Identifiants
pubmed: 36002181
pii: 9/1/e001340
doi: 10.1136/bmjresp-2022-001340
pmc: PMC9412043
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Intern Emerg Med. 2021 Oct;16(7):1959-1965
pubmed: 33646507
Int J Clin Pract. 2021 Oct;75(10):e14759
pubmed: 34455674
Tidsskr Nor Laegeforen. 2020 Apr 10;140(7):
pubmed: 32378844
J Clin Med. 2022 Feb 03;11(3):
pubmed: 35160272
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Caspian J Intern Med. 2020 Fall;11(Suppl 1):536-543
pubmed: 33425272
Sao Paulo Med J. 2021 Mar-Apr;139(2):170-177
pubmed: 33681885
Infect Dis (Lond). 2021 Aug;53(8):640-642
pubmed: 33691577
EClinicalMedicine. 2021 May;35:100828
pubmed: 33937729
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Pulmonology. 2022 Jan-Feb;28(1):13-17
pubmed: 34049831
BMJ. 2020 Sep 9;370:m3339
pubmed: 32907855
Ann Emerg Med. 2017 Apr;69(4):475-479
pubmed: 28110990
Crit Care Explor. 2020 Jul 29;2(8):e0173
pubmed: 32766566
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355
pubmed: 32667669
Thorax. 2021 Jul;76(7):696-703
pubmed: 33692174
BMJ. 2015 Jan 07;350:g7594
pubmed: 25569120
J Intern Med. 2006 Jul;260(1):93-101
pubmed: 16789984
BMJ Open Respir Res. 2020 Dec;7(1):
pubmed: 33293361
Thorax. 2003 May;58(5):377-82
pubmed: 12728155
Swiss Med Wkly. 2021 Jan 15;151:w20458
pubmed: 33715144
J Med Virol. 2020 Nov;92(11):2272-2273
pubmed: 32530534
Int J Clin Pract. 2021 Dec;75(12):e13705
pubmed: 32931634
Front Med (Lausanne). 2022 Mar 02;9:779516
pubmed: 35308539
Resusc Plus. 2020 Dec;4:100042
pubmed: 33403367
Intensive Care Med. 2020 Oct;46(10):1924-1926
pubmed: 32671470
Eur Respir J. 2020 Sep 10;56(3):
pubmed: 32675205
Chest. 2022 Apr;161(4):927-936
pubmed: 34740594
Thorax. 2022 Jun;77(6):606-615
pubmed: 34810237
Crit Care. 2012 Jul 27;16(4):R141
pubmed: 22839689
Scand J Trauma Resusc Emerg Med. 2020 Jul 13;28(1):66
pubmed: 32660623
Anaesthesia. 2020 Jul;75(7):928-934
pubmed: 32246838
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Int J Infect Dis. 2021 Oct;111:108-116
pubmed: 34416403
Clin Microbiol Infect. 2021 Jul;27(7):1037.e1-1037.e8
pubmed: 33813111
Wien Med Wochenschr. 2022 Jun;172(9-10):211-219
pubmed: 34185216
J Gen Intern Med. 2021 May;36(5):1338-1345
pubmed: 33575909
Intensive Care Med. 2021 Dec;47(12):1426-1439
pubmed: 34585270
Stud Health Technol Inform. 2022 May 25;294:317-321
pubmed: 35612084
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Sci Rep. 2021 Sep 20;11(1):18638
pubmed: 34545103
Crit Care Med. 2009 Apr;37(4):1317-21
pubmed: 19242333
J Crit Care. 2016 Oct;35:200-5
pubmed: 27481760